{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T16:12:46Z","timestamp":1668183166868},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,9,14]]},"DOI":"10.18632\/oncotarget.28274","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T14:22:00Z","timestamp":1663251720000},"page":"1034-1042","source":"Crossref","is-referenced-by-count":1,"title":["Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV\/HPV related metastatic anal cancer and <i>MLH1<\/i> mutation"],"prefix":"10.18632","volume":"13","author":[{"given":"Melanie","family":"Demes","sequence":"first","affiliation":[{"name":"Dr. Senckenbergisches Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"},{"name":"Universit\u00e4res Centrum f\u00fcr Tumorerkrankungen (UCT), Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Pession","sequence":"additional","affiliation":[{"name":"Universit\u00e4res Centrum f\u00fcr Tumorerkrankungen (UCT), Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"},{"name":"Klinik f\u00fcr Allgemein- und Viszeralchirurgie, Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Jeroch","sequence":"additional","affiliation":[{"name":"Dr. Senckenbergisches Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falko","family":"Schulze","sequence":"additional","affiliation":[{"name":"Dr. Senckenbergisches Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"},{"name":"Universit\u00e4res Centrum f\u00fcr Tumorerkrankungen (UCT), Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Eichler","sequence":"additional","affiliation":[{"name":"Universit\u00e4res Centrum f\u00fcr Tumorerkrankungen (UCT), Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"},{"name":"Institut f\u00fcr Diagnostische und Interventionelle Radiologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Martin","sequence":"additional","affiliation":[{"name":"Universit\u00e4res Centrum f\u00fcr Tumorerkrankungen (UCT), Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"},{"name":"Klinik f\u00fcr Strahlentherapie und Onkologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wild","sequence":"additional","affiliation":[{"name":"Dr. Senckenbergisches Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"},{"name":"Universit\u00e4res Centrum f\u00fcr Tumorerkrankungen (UCT), Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Waidmann","sequence":"additional","affiliation":[{"name":"Universit\u00e4res Centrum f\u00fcr Tumorerkrankungen (UCT), Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"},{"name":"Medizinische Klinik 1, Schwerpunkte Gastroenterologie und Hepatologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt 60590, Germany"},{"name":"Centrum f\u00fcr H\u00e4matologie und Onkologie, Frankfurt 60389, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/ije\/dyw276","article-title":"International trends in anal cancer incidence rates","volume":"4","author":"Jemal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"12","author":"Franceschi","year":"2009","journal-title":"Int J Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/jnci\/djs371","article-title":"Impact of the HIV epidemic on the incidence rates of anal cancer in the United States","volume":"10","author":"Engels","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"1","author":"Pierart","year":"1997","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"iii10","DOI":"10.1093\/annonc\/mdu159","article-title":"Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"2","author":"Arnold","year":"2014","journal-title":"Ann Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"3","author":"Welch","year":"2020","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11912-018-0698-6","article-title":"Systemic Therapies for Advanced Squamous Cell Anal Cancer","volume":"2","author":"Rao","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"2","author":"Saraf","year":"2017","journal-title":"Ann Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"1","author":"Vence","year":"2017","journal-title":"Lancet Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/CJI.0000000000000240","article-title":"Nivolumab Treatment for Cancers in the HIV-infected Population","volume":"4","author":"Chiao","year":"2018","journal-title":"J Immunother"},{"key":"11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review","volume":"5","author":"Kim","year":"2019","journal-title":"JAMA Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"37","author":"Zaheer","year":"2015","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","article-title":"Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration","volume":"2","author":"Heo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ctrv.2018.02.008","article-title":"Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians","volume":"6","author":"Badoual","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/QAI.0b013e3181fbab9f","article-title":"Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment","volume":"5","author":"Kohrgruber","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1182\/blood-2010-12-328070","article-title":"Responsiveness of HIV-specific CD4 T cells to PD-1 blockade","volume":"11","author":"Kaufmann","year":"2011","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"3","author":"Lavol\u00e9","year":"2019","journal-title":"AIDS"},{"key":"18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1158\/1541-7786.MCR-17-0735","article-title":"Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers","volume":"1","author":"Lenz","year":"2018","journal-title":"Mol Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10689-017-0031-9","article-title":"Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations","volume":"1","author":"Shia","year":"2018","journal-title":"Fam Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/humu.21301","article-title":"Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair","volume":"3","author":"Plotz","year":"2010","journal-title":"Hum Mutat"},{"key":"21","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1002\/cam4.3001","article-title":"Molecular profiling of gastric cancer in a population with high HIV prevalence reveals a shift to MLH1 loss but not the EBV subtype","volume":"9","author":"Kelly","year":"2020","journal-title":"Cancer Med"},{"key":"22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/ijc.26440","article-title":"Oncogenic PIK3CA mutations in colorectal cancers and polyps","volume":"13","author":"Montgomery","year":"2012","journal-title":"Int J Cancer"},{"key":"23","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.7150\/jca.37437","article-title":"Prevalence and characteristics ofmutation in mismatch repair-deficient colorectal cancer","volume":"1","author":"Ying","year":"2020","journal-title":"J Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/0284186X.2019.1664764","article-title":"mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis","volume":"5","author":"Yang","year":"2020","journal-title":"Acta Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3892\/or.2016.5323","article-title":"High concordance rate of KRAS\/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases","volume":"3","author":"Akagi","year":"2017","journal-title":"Oncol Rep"},{"key":"26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.6004\/jnccn.2019.7308","article-title":"Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer","volume":"1","author":"Xia","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"27","doi-asserted-by":"publisher","first-page":"BSR20190730","DOI":"10.1042\/BSR20190730","article-title":"Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study","volume":"3","author":"Wang","year":"2019","journal-title":"Biosci Rep"},{"key":"28","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer","volume":"37","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"2","author":"Piha-Paul","year":"2020","journal-title":"Lancet Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-16-2017","article-title":"Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma","volume":"2","author":"Martin","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T14:22:04Z","timestamp":1663251724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,9,14]]}},"alternative-id":["28274"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28274","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]}}}